Treatment of premature ejaculation with sertraline hydrochloride

Int J Impot Res. 1998 Sep;10(3):181-4; discussion 185. doi: 10.1038/sj.ijir.3900344.

Abstract

Purpose: To evaluate the efficacy of sertraline hydrochloride in the drug treatment of premature ejaculation (P.E.).

Materials and method: Forty-six normally potent men, aged 22 to 63 years (mean 42 years) with premature ejaculation were treated with oral sertraline in a dose ranging study. All men were either married or in a stable relationship. The mean ejaculatory interval was 1 minute (range 0-5 min). All men were started on Sertraline 25 mg daily and were increased to 50 mg after 3 weeks and 100 mg after a further 3 weeks. None of the men received any formal psychosexual therapy.

Results: With a dose of 25 mg, the mean ejaculatory interval increased to 7.6 min (range 0-20 min). With a dose of 50 mg, the mean ejaculatory interval increased to 13.1 min (range 7 min-anejaculation) with 4 men experiencing anejaculation. With a dose of 100 mg, the mean ejaculatory interval increased to 16.4 min (range 7 min-anejaculation), 10 men experiencing anejaculation. With a dose of 25 mg, 1 man described transient dizziness. With a dose of 50 mg, 1 man described some drowsiness and anorexia and 1 man experienced minor dyspepsia. With a dose of 100 mg, 2 men described erectile dysfunction and reduced libido, 2 men described transient drowsiness and anorexia, 2 men experienced minor dyspepsia and 2 men described feelings of anxiety.

Conclusion: Sertraline appears to be a useful agent in the pharmacological treatment of premature ejaculation.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Ejaculation*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Serotonin Uptake Inhibitors / therapeutic use*
  • Sertraline / therapeutic use*
  • Sexual Dysfunction, Physiological / drug therapy*

Substances

  • Serotonin Uptake Inhibitors
  • Sertraline